[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603968":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":21,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":58,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"epidemiology and medical treatment strategies","Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Mathilde Puges, MD","CONTACT","+335 56 79 55 36","mathilde.puges@u-bordeaux.fr",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Carole Vignals, MD","carole.vignals@aphp.fr",[22],{"facility":23,"status":7,"city":24,"state":7,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"CHU Bordeaux","Bordeaux","France","FR",{"type":28,"coordinates":29},"Point",[30,31],-0.58046,44.84124,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100603968",false,"NCT07143409","Fungal Vascular Graft Infections, French Multicenter Retrospective Study","FUNGIVAS","Inclusion Criteria:\n\n* Patients aged ≥ 18 years old with diagnosis of vascular graft and endograft infections (VGEI) in accordance to MAGIC criteria with diagnosis of proven invasive fungal infection according to EORTC criteria.\n* No opposition to re-use data.\n\nExclusion Criteria:\n\n* Patient previously treated for fungal VGEI\n* Patient with suspected VGEI diagnosis based solely on prosthesis implantation in an infected site\n* Poor understanding of French.\n* Patient under legal protection.","ALL","18 Years",{"count":46,"type":47},300,"ESTIMATED","OBSERVATIONAL","Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France over a 10 year's period in order to describe their epidemiology, clinical features, therapeutic management and outcomes. Focusing on Candida spp. VGEIs, we aim to determine prognosis factors associated with therapeutic management",[51,52],"Fungal Infection","Vascular Grafting",[54,55,56,57],"vascular graft infection","vascular endograft infection","fungi","Candida","NOT_YET_RECRUITING","2025-12-09",{"date":61,"type":62},"2025-12-16","ACTUAL",{"date":64,"type":47},"2026-01",{"date":66,"type":47},"2027-05",{"name":5,"class":6},1]